Nanobiotix Shares Up 3.73%, Targeting the 50-Day Moving Average of €32.70
The French biotech firm is regaining momentum this late morning, after several sessions marked by the digestion of its annual rally. The stock is among the notable risers on the SBF 120, in a Parisian market that is also trending upwards.
A Rebound Bringing the Price Close to the 50-Day Moving Average
Nanobiotix shares are up 3.73% at €32.28 during the session, among the strongest gains on the SBF 120. The stock has clearly moved back above its MM20 (€30.42) and is approaching its MM50 at €32.70, which remains just out of reach (-1.28%). The RSI at 49 indicates a return to a neutral zone, after several sessions of selling pressure.
Today's rebound mitigates the monthly decline, which remains at -5.17%, while the performance over three months is at +21.81% and over one year at more than 700%. The price continues to be significantly above the MM200 (€23.42), by nearly 38%, reflecting the magnitude of the annual journey.
Rising Bearish Pressure in a Still Favorable Clinical Context
According to statements reviewed, two funds now cumulatively hold 1.12% of the capital sold short, after a rapid increase of just over one point in thirty days. The level remains modest in absolute terms, but the speed of accumulation reflects a measured rise in bearish pressure on the stock, without signaling massive distrust on its own. In the background, the biotech had strengthened its cash reserves in early June through a capital increase of €86.1 million, bringing net liquidity to €42.1 million as of March 31, 2026.
During the first quarter of 2026 publication (June 2, 2026), the company highlighted the progress of clinical studies on JNJ-1900 (NBTXR3) and the strengthening of the Nanoprimer platform, while noting the limited progress of the current standard in inoperable lung cancer as the main risk. The MM50 at €32.70 will be the next technical threshold to watch to confirm the end of the digestion phase.
